

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Andrea Casadei Gardini

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Medical Doctor

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
Alma Mater Studiorum - Università di Bologna, Bologna	Medicine and Surgery	09/2008	General Medicine
Università degli studi di Ferrara, Ferrara	Oncology Specialist	06/2014	Oncology

A. Personal Statement

I currently serve as Associate Professor at Vita e Salute San Raffaele University and as Head of Liver Medical Oncology group at San Raffaele Hospital, specialized in the diagnosis and treatment of hepatobiliary tumors, including hepatocellular carcinoma and biliary tract cancers. During the last 20 years I put all my effort into the development of a concrete clinical and scientific career in the field with the support of a solid network with all clinicians connected to the pathologies of interest.

One of the primary areas of my research involves the molecular and genomic characterization of biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinoma, as well as gallbladder cancer, and their correlation with clinical outcomes. Specifically, my research aims to identify prognostic and predictive factors that can improve patients' stratification, focusing on large, real-world cohorts of advanced biliary tract cancer patients outside the confines of prospective randomized trials. By analyzing these patient populations, my primary goal is to identify clinical and molecular markers that can predict responses to specific treatments, ultimately improving patient care and outcomes in an optic of precision medicine. International and external collaboration has been a key component of my research efforts. I have had the opportunity to work with leading institutions in Europe, Asia, and the United States, building multinational research networks to analyze a broad range of clinical data and genetic profiles. These collaborations have significantly expanded the scope of my research, enabling me to integrate diverse patient populations and clinical settings. This approach is essential to gaining a more comprehensive understanding of the global landscape of biliary tract cancers and their molecular heterogeneity.

B. Positions, Scientific Appointments, and Honors

POSITIONS:

POSITIONs		
Date	Position	Institution
from 2023/ongoing	Associate Professor	Università Vita Salute San Raffaele
from 2020/ongoing	RTDB	Università Vita Salute San Raffaele
from 2020/ongoing	head of hepatobiliary oncology unit	San Raffaele Hospital
From 17/12/2018 to 30/09/2020	RTDB	University of Modena
from 27/03/2017 to 27/12/2017	Research fellow	Clinica Universidad de Navarra, Unit of Hepatology; Pamplona, Spain
From 05/08/2014 to 16/12/2018	Oncologist	Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS

Relevant Grant awarded:

1. Principal investigator of the grant young investigator (Italian Ministry of Health). "Estimating the risk for cardiac toxicity in patients undergoing anticancer therapies: a new dynamic risk algorithm integrating levels of cardiovascular serum biomarkers." GR-2013-0235547.
2. Collaborator of the grant AIRC 2020: Identification of circulating biomarkers for patient allocation to the best treatment in hepatocellular carcinoma.
3. Co-principal investigator of the grant Fondo de investigation en salud; Instituto de salud Carlos III 2020 in Spain: NEW MECHANISMS AND TARGETS IN HEPATOCELLULAR CARCINOMA DEVELOPING IN THE CONTEXT OF NASH. (MECANASH).
4. Co-principal investigator of the grant Grant with ministry of Health of Spain 2021: Blocking the unfolded protein response: a novel strategy to increase the efficacy of immune check-point inhibitors in HCC.
5. Co-principal investigator of the grant Fondo de investigation en salud; Instituto de salud Carlos III 2022 in Spain: inhibitor CM272 as new targte in patients with hepatocellular carcinoma.
6. Collaborator of the grant PNNR 2022: Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization in combination with CisGem and Durvalumab (PM-CARE)
7. Principal investigator of unit of the grant TRANSCAN 2023: Novel translational approaches to tackle the challenges of hard-to- treat cancers from early diagnosis to therapy

Reviewer for funding agencies: French association for the study of the liver (AFEF). 2019 and 2022; The French National Cancer Institute 2025

Patent

1. **Patent holder number 102021000021455 (06/08/2021):** HOXD8 as a candidate gene biomarker for low invasive detection of biliary tract cancers, selected by a machine-learning approach

Member of editorial Board

1. Guest editor: Gastroenterology Research and Practice Special Issue on: Recent Advances in Hepatobiliary Tumours. From 15/01/2016 to 15/12/2016
2. Editor: Gastroenterology Research and Practice; From 05/03/2018-until now.
3. Guest editor: Gastroenterology Research and Practice Special Issue on: Recent Advances in Hepatobiliary Tumours
4. Guest editor: Oxidative Medicine and Cellular Longevity. Special Issue: "Oxidative Molecular Mechanisms Underlying Liver Diseases: from Systems Biology to the Personalized Medicine (OMLD)."
5. Guest editor Recent Research on Gastrointestinal Carcinoma; Cancers

6. Guest editor Theranostic Advances in Hepatobiliary Tumors; Cancers
7. Editor "radiations": <https://www.mdpi.com/journal/radiations/editors>
8. Editor Frontiers Oncology
<https://www.frontiersin.org/search/journal/oncology?query=Casadei+Gardini&tab=People&origin=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Foncology%23editorial-board>
9. Guest editor "New Advances in Hepatocellular Carcinoma: From the Past to the Future"
https://www.mdpi.com/journal/cancers/special_issues/New_Advances_HCC
10. Youth editorial board of hepatoma research from November 2020
11. Different Immunophenotype and Prognosis in Hepatocellular Carcinoma;
12. HPB cancer international <https://rasayely-journals.com/index.php/hpbci/editorial-board>

C. Contributions to Science

Author of more than 250 peer reviewed publications.

RELEVANT PUBLICATIONS:

1. Rimini M, Fornaro L, Prinzi FL, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquez MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Corallo S, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Vitiello F, Himmelsbach V, Landriscina M, Djaballah SA, Tesini G, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study. *Int J Cancer*. 2025 May 19. doi: 10.1002/ijc.35481. Online ahead of print.
2. Rimassa L, Lamarca A, O'Kane GM, Edeline J, McNamara MG, Vogel A, Fassan M, Forner A, Kendall T, Adeva J, Casadei-Gardini A, Fornaro L, Hollebecque A, Lowery MA, Macarulla T, Malka D, Mariamidze E, Niger M, Ustav A, Bridgewater J, Macias RIR, Braconi C. Correction to "New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe" [*The Lancet Regional Health - Europe*, volume 50, March 2025, 101170]
3. Oyon D, Lopez-Pascual A, Castello-Urbe B, Uriarte I, Orsi G, Llorente S, Elurbide J, Adan-Villaescusa E, Valbuena-Goicelaya E, Irigaray-Miramón A, Latasa MU, Martínez-Pérez LA, Bonetti LR, Prosper F, Ponz-Sarvisé M, Vicent S, Pineda-Lucena A, Ruiz-Clavijo D, Sangro B, Larracochea UA, Tian TV, Casadei-Gardini A, Amat I, Arechederra M, Berasain C, Urman JM, Avila MA, Fernández-Barrena MG. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. *J Exp Clin Cancer Res*. 2025 Jan 15
4. Di Gaeta E, Olivieri M, Savi A, Magnani P, Canevari C, Gusmini S, Palumbo D, Guazzarotti G, Augello L, Calabrese F, Steidler S, Cipriani F, Rimini M, Casadei-Gardini A, Aldrighetti L, Chiti A, De Cobelli F.. Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and (99m)Tc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization (90)Y PET/CT. *Radiol Med*. 2025 Apr
5. Rimini M, Foti S, Camera S, Rossari F, Vitiello F, Lo Prinzi F, Aldrighetti L, De Cobelli F, Pedica F, Arcidiacono PG, Persano M, Cascinu S, Casadei-Gardini A. Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution. *Oncology*. 2024 Dec 6:1-22. doi: 10.1159/000541891. Online ahead of print.
6. Filippi R, Brandi G, Casadei-Gardini A, Leone F, Silvestris N, Satolli MA, Salani F, Sperti E, Lutrino SE, Aprile G, Santini D, Scartozzi M, Faloppi L, Palloni A, Deserti M, Tavoroli S, Rimini M, Brunetti O, Spadi R,

Ilaria D, Di Maio M. Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance. *Cancer Invest.* 2025 Jan

7. Lo Prinzi F, Rossari F, Silletta M, Foti S, Camera S, Vitiello F, Amadeo E, De Cobelli F, Aldrighetti L, Rimini M, Casadei-Gardini A. Intermediate hepatocellular carcinoma: new horizons and prospects for our patients. *Expert Rev Gastroenterol Hepatol.* 2024 Oct
8. Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Fornaro L, De Rosa A, Lavacchi D, Rossari F, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Viola MG, Silvestro L, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population. *Oncologist.* 2025 Mar 10
9. Elurbide J, Colyn L, Latasa MU, Uriarte I, Mariani S, Lopez-Pascual A, Valbuena E, Castello-Urbe B, Arnes-Benito R, Adan-Villaescusa E, Martinez-Perez LA, Azkargorta M, Elortza F, Wu H, Krawczyk M, Schneider KM, Sangro B, Aldrighetti L, Ratti F, Casadei Gardini A, Marin JJG, Amat I, Urman JM, Arechederra M, Martinez-Chantar ML, Trautwein C, Huch M, Cubero FJ, Berasain C, G Fernandez-Barrena M, Avila MA. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma. *Gut.* 2024 Dec 10
10. D'Abundo L, Bassi C, Callegari E, Moshiri F, Guerriero P, Michilli A, Mora F, Gardini AC, Sangiovanni A, Piscaglia F, Sabbioni S, Gramantieri L, Negrini M. Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy. *Sci Rep.* 2024 Aug 9
11. Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon HJ, Braconi C, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Salani F, De Rosa A, Lavacchi D, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population. *Eur J Cancer.* 2024 Sep
12. Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study. *Target Oncol.* 2024 May

I authorize the use of my personal data as established by EU Regulation n 2016/679
27 May 2026

